This information was provided by CMW Media
Send your Press Release here.
President Trump just told Jeff Sessions to sue certain drug companies for contributing to the U.S. opioid crisis. In response, Sessions said the Justice Department is “looking at various different legal avenues to go after abusive companies.”
The DEA is also pushing to reduce the amount of certain opioid drugs—such as oxycodone, hydrocodone, morphine, fentanyl and others—that are produced in the U.S. Surprisingly, the DEA is simultaneously moving to more than quintuple the amount of cannabis that can legally be grown in the U.S. for research purposes—from roughly 1,000 pounds in 2018 to more than 5,400 pounds next year.
Why all the government interest surrounding marijuana?
Cannabidiol (CBD) is a chemical compound found in cannabis and is used to treat a number of conditions, and is noted for its anti-inflammatory and neuroprotective properties. KannaLife Sciences, who holds the exclusive license from the federal government to commercialize a medical marijuana patent currently held by the National Institutes of Health (NIH), is working on a solution using a CBD-derivative they hope will one day help people avoid opioids and treat their pain in a safer way.
Kannalife recently received a grant from the NIH to study the use of their patented CBD-derivative KLS-13019 to treat pain.
Want to speak to a Kannalife exec about changing government stance on marijuana, along with Kannalife’s groundbreaking research?